Måndag 26 Januari | 19:08:38 Europe / Stockholm
Svenska | English

BioStock

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

BioInvent reports promising response rate in ovarian cancer
2026-01-09 07:57:00

BioInvent International recently announced promising interim results from one of its ongoing Phase IIa trials. The data shows that the company's lead drug candidate, BI-1808, in combination with Keytruda, achieved an overall response rate of 24 per cent in heavily pre-treated ovarian cancer patients – a result that stands out in a patient group with few effective treatment options. To learn more, BioStock turned to CEO Martin Welschof for a comment.

Read the full article at biostock.se:
https://biostock.se/en/2026/01/bioinvent-rapporterar-lovande-respons-vid-aggstockscancer/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter 
Follow BioStock on social media: LinkedIn and Facebook!  
 
About BioStock 
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden